세계의 무좀 치료제 시장(2023-2030년)

Overview

Global Athlete's Foot Drugs Market reached US$ 1.2 billion in 2022 and is expected to reach US$ 2.1 billion by 2030 growing with a CAGR of 7.8% during the forecast period 2023-2030. The trend such as the shift towards active lifestyle such as growing participation in sport and physical activities develops the risk of exposure to public showers where fungus can trive, is expected to dominate the global athlete's foot drugs market.

The global athlete's foot drugs market has grown significantly in recent years and is projected to continue on its upward trend. The market is undergoing a transformational period, influenced by several significant trends such as the growing consumer preference towards natural and organic treatment options that leads to development of herbal antifungal products.

Furthermore, the rising prevalence of infectious disease such as fungal infections and diabetes, growing awareness health and hygiene of foot, moreover availability of OTC products are driving up the athlete's foot drugs market size. The growing research activities about the disease and presence of establish heathcare infrastructure due to access to quality medical professional are some of the factors in demand from North American regions. With significant competitors like Novartis AG, Bayer AG, Vibcare Pharma Pvt. Ltd., and others actively operating in the market.

Dynamics

The Increasing Prevalence of Diabetic People to Drive the Growth of the Athlete's Foot Drugs Market

The increasing prevalence of diabetes around the globe is expected to significantly drive the global athlete's foot drugs market. Diabetes is a chronic, metabolic disease that elevates the levels of blood glucose level in body, that leads to weakens the immune system, impairs circulation, and causes neuropathy, elevating the risk of infections and necessitating prompt treatment.

For instance, according to World Health Organization 2023 report, approximately 422 million people around the world are suffering from diabetes and the majority of cases are seen in low-and middle-income countries, that has led to 1.5 million deaths. As during athlete's foot dryness, cracking, and reduced sensation of skin occurs that leds to more vulnerability of disease having diabtes and can be recurrent too. Thus, as the prevalence of diabetes propel the demand for effective treatment for the people suffering diabetic-specific challenges within the athlete's foot drugs market is expected to drive over the forecast period.

The Rising Prevalence of Obesity will Drive the Athlete's Foot Drugs Market Growth

The growing prevalence of obese people across the globe is expected to boost the market of athlete's foot drugs. Obesity has become a major issue in recent years, and it can have severe consequences on feet. For instance, according to World Health Organization 2022 report, approximately 1 billion people globally are obesed that accounts 650 million adults, 340 million adolescents and 39 million children.

Sprained ankles, general foot fatigue, blisters, calluses, and athlete's foot are some of the most common foot disorders in obese patients. Overweight people may find it difficult to exercise, which is essential for keeping a healthy weight. Moreover, obesity frequently causes skin wrinkles and increased moisture in these regions, creating an environment favorable to fungal growth. Thus, as the obesed people population increases, there is major need of effective drugs to manage and alleviate the symtoms that are likely to occur and thereby driving the market over the foreseeable future.

The Growing Geriatric Population will Drive the Athlete's Foot Drugs Market Growth

The increasing elderly population is expected to drive the athlete's foot market owing to the factors such as the people age, they are more susceptible to have poor foot health, along with other chronic disease complications that lead to foot related problems. For instance, according to World Health Organization 2022 report, 1 in 6 people in the world will age above 60 years by 2030.

Furthermore, the people aging above 60 will increase from 1 billion in 2020 to 1.4 billion. This disorder is more prevalent in males compared to female population. Thus, there is increase the need for efficient drug treatments to address their individual vulnerabilities and the discomfort and risks associated with fungal diseases such as athlete's foot.

The Side Effects Associated with the Athlete's Foot Drugs Will Hamper the Growth of the Market

The athlete's foot drugs market is expected to be hamper owing to the factors such as side effects from the drugs. The most prevalent adverse reactions of athlete's foot medications are burning, stinging, swelling, irritation, redness, pimple-like lumps, soreness, or flaking of the treated area. For instance, Ketoconazole an antifungal drug that works by killing fungi that and is mostly given to treat athlete foot disease has some side effects such as blistering, crusting, irritated or red skin.

Moreover, corticosteroid used to treat athlete foot disease can have major side effects unusual patterns in ringworm rashes, like this "double-edged" pattern that is several inches wide. Long term use of these corticosteroid creams combination may lead to severe redness and burning with ringworm. Thus, owing to the above factors the market is expected to face a major restraint over the forecast period.

Segment Analysis

The global athlete's foot drugs market is segmented based on type, product type, drug class, distribution channel, and region.

Owing to its Better Effectiveness, the Anti Fungal Segment Accounted for Approximately 42.8% of the Athlete's Foot Drugs Market Share

The anti fungal segment is poised to dominate the athlete's foot drugs market as it remains a first-line and preferred medical treatment for athlete's foot drugs owing to its effectiveness, advancements in formulations, and better efficacy for treating athlete's foot disorder. The most commonly used drugs are clotrimazole, miconazole, tolnaftate or terbinafine, fluconazole, itraconazole.

Furthermore, the availability of over-the-counter (OTC) drugs in the forms of creams, gels, sprays makes antifungal class a preferred choice. Terbinafine (Lamisil AT), an antifungal, has been demonstrated to be particularly effective. Clotrimazole (Lotrimin AF) is another possibility. Moreover, new product approval will propel the market forward, for instance, in May 2022, Bayer's Consumer Health division announced the launch of the new and improved Canesten anti-fungal treatment solution in India. This medication provides relief from ringworm, jock itch, skin candidiasis, athlete's foot, erythrasma and fungal nail infection. Thus, owing to the above factors the segment is expected to dominate over the forecast period.

Geographical Penetration

North America Accounted for Approximately 39.5% of the Market Share in 2022, Owing to the Prevalence of Athlete's Foot and Increasing Research Activities

North America, particularly the U.S., dominates the global athlete's foot drugs market due to its presence of established market players, along with increasing R&D activities. Furthermore, the increasing number of clinical trials led to novel treatments for better patient outcomes.

The rising prevalence of fungal disease such as dermatophytosis due to which athlete's foot is caused in U.S. is expected to drive the region. For instance, according to Center for Disease Control and Prevention article of 2023, dermatophytosis (ringworm) has resulted with 690 hospitalization, and 4,981,444 in U.S. Thus, this increasing number of hospitalization can be restricted by providing appropriate drug for better health outcomes.

Morover, increasing number of R&D activities and clinical trial in this region will lead to advancements in treatment options. For instance, DermBiont, Inc., a clinical stage precision dermatology company is conducting a clinical trial to evaluate the safety and efficacy of DBI-001 Gel, DBI-002 Gel, and Aqueous Gel in subjects with tinea pedis based on Whole Genome Sequencing (WGS) and Quantitative Polymerase Chain Reaction (qPCR), and comparison between Quantitative Polymerase Chain Reaction (qPCR) and Potassium Hydroxide (KOH). The trial is randomized and observer-blind, with an Aqueous Gel as a control group. The gels will be used daily for roughly 6-8 days during the study. Thus, owing to the factor stated above, the market in this region is expected to grow over the forecast period.

Competitive Landscape

The major global players in the athlete's foot drugs market include: Novartis AG, Vibcare Pharma Pvt. Ltd., Bayer AG, Taro Pharmaceutical Industries Ltd, GLENMARK PHARMACEUTICALS LTD., Abigail Healthcare Pharmaceutical, Sebela Pharmaceuticals, ANI Pharmaceuticals, Inc. and Perrigo Company plc among others.

COVID-19 Impact Analysis

COVID-19 most likely raises the risk of fungal infections such as athlete's foot due to its effect on the immune system and the fact that COVID-19 therapies (such as steroids and other medicines) might decrease the body's defenses against fungus.

Research conducted by the Centers for Disease Control and Prevention discovered that patients brought to the hospital with covid-19 were more likely to die if they also had a fungal infection. Patients with covid-19 and a fungal infection died at a rate of 48.5% during the pandemic, compared to 12.3% in patients with only fungal infections.

Regardless of the precise fungal pathogens involved, dual covid-19 and fungal infections resulted in longer hospital admissions, greater rates of critical care treatment, more usage of invasive mechanical ventilation, and more mortality. Thus, Covid-19 has created a major impact on athlete's foot market.

By Type

• Toe Web Infection
• Moccasin-type Infection
• Vesicular-type Infection
• Ulcerative Infection

By Product Type

• Topical Creams and Ointments
• Sprays
• Lotions
• Oral Medications
• Others

By Drug Class

• Antifungal Agents
• Corticosteroid
• Antibiotics
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region

• North America
  • U.S.
  • Canada
  • Mexico

• Europe
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe

• South America
  • Brazil
  • Argentina
  • Rest of South America

• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific

• Middle East and Africa

Key Developments

• On June 20, 2022, Kerasal announced the launch of a new Athlete's Foot product line that includes a unique formula with 5-in-1 advantages to not only treat and heal most athlete's foot but also improve skin appearance and support a healthy footcare routine. The new Athlete's Foot products, which include the Athlete's Foot Invisible Powder Spray and Athlete's Foot Silky Clear Gel, are the latest additions to the brand's foot care range.
• On November 1, 2022, Zydus received approval from the Subject Expert Committee (SEC) of the Central Drug Standard Control Organization (CDSCO) to manufacture and market the antifungal drug Naftifine HCL 2% Cream in the country for the treatment of superficial fungal infections of the skin (Tinea corporis and Tinea cruris).
• On December 22, 2022, Synokem Pharmaceutical has received approval from the Central Drug Standard Control Organization's (CDSCO) Subject Expert Committee (SEC) to manufacture and market the antifungal drug Naftifine HCL Cream 2% w/w for the treatment of superficial fungal infection of the skin.

DMI Opinion

The global athlete's foot drugs market appears to be on the rise, owing to factors such as a change toward an active lifestyle, the prevalence of infectious diseases and diabetes, and an aging population. Consumer preferences for natural remedies and the development of new treatment choices reflect the market's breakthrough period. The possibility of side effects and the challenges posed by the COVID-19 pandemic, on the other hand, should not be neglected. The market's outcome will be influenced by how well these difficulties are addressed, as well as how effectively the industry continues to develop and meet consumer needs.

Why Purchase the Report?

• To visualize the global athlete's foot drugs market segmentation based on type, product type, drug class, distribution channel, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of athlete's foot drugs market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available in excel consisting of key products of all the major players.

The global athlete's foot drugs market report would provide approximately 53 tables, 54 figures and 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Type
• 3.2. Snippet by Product Type
• 3.3. Snippet by Drug Class
• 3.4. Snippet by Distribution Channel
• 3.5. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. The Increasing Prevalence of Diabetic People
    • 4.1.1.2. The Rising Prevalence of Obesity
    • 4.1.1.3. The Growing Geriatric Population
  • 4.1.2. Restraints
    • 4.1.2.1. The Side Effects Associated with the Athlete's Foot Drugs
  • 4.1.3. Opportunity
    • 4.1.3.1. Increasing Demand for Personalized Medicine
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's 5 Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID-19
  • 6.1.2. Scenario During COVID-19
  • 6.1.3. Scenario Post COVID-19
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 7.1.2. Market Attractiveness Index, By Type
• 7.2. Toe Web Infection*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Moccasin-type Infection
• 7.4. Vesicular-type Infection
• 7.5. Ulcerative Infection

8. By Product Type

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 8.1.2. Market Attractiveness Index, By Product Type
• 8.2. Topical Creams and Ointments*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Sprays
• 8.4. Lotions
• 8.5. Oral Medications
• 8.6. Others

9. By Drug Class

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 9.1.2. Market Attractiveness Index, By Drug Class
• 9.2. Antifungal Agents*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Corticosteroid
• 9.4. Antibiotics
• 9.5. Others

10. By Distribution Channel

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.1.2. Market Attractiveness Index, By Distribution Channel
• 10.2. Hospital Pharmacies*
  • 10.2.1. Introduction
  • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 10.3. Retail Pharmacies
• 10.4. Online Pharmacies

11. By Region

• 11.1. Introduction
  • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 11.1.2. Market Attractiveness Index, By Region
• 11.2. North America
  • 11.2.1. Introduction
  • 11.2.2. Key Region-Specific Dynamics
  • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.2.7.1. U.S.
    • 11.2.7.2. Canada
    • 11.2.7.3. Mexico
• 11.3. Europe
  • 11.3.1. Introduction
  • 11.3.2. Key Region-Specific Dynamics
  • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.3.7.1. Germany
    • 11.3.7.2. U.K.
    • 11.3.7.3. France
    • 11.3.7.4. Spain
    • 11.3.7.5. Italy
    • 11.3.7.6. Rest of Europe
• 11.4. South America
  • 11.4.1. Introduction
  • 11.4.2. Key Region-Specific Dynamics
  • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.4.7.1. Brazil
    • 11.4.7.2. Argentina
    • 11.4.7.3. Rest of South America
• 11.5. Asia-Pacific
  • 11.5.1. Introduction
  • 11.5.2. Key Region-Specific Dynamics
  • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.5.7.1. China
    • 11.5.7.2. India
    • 11.5.7.3. Japan
    • 11.5.7.4. Australia
    • 11.5.7.5. Rest of Asia-Pacific
• 11.6. Middle East and Africa
  • 11.6.1. Introduction
  • 11.6.2. Key Region-Specific Dynamics
  • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

12. Competitive Landscape

• 12.1. Competitive Scenario
• 12.2. Market Positioning/Share Analysis
• 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

• 13.1. Novartis AG*
  • 13.1.1. Company Overview
  • 13.1.2. Product Portfolio and Description
  • 13.1.3. Financial Overview
  • 13.1.4. Key Developments
• 13.2. Vibcare Pharma Pvt. Ltd.
• 13.3. Bayer AG
• 13.4. Taro Pharmaceutical Industries Ltd
• 13.5. GLENMARK PHARMACEUTICALS LTD.
• 13.6. Abigail Healthcare Pharmaceutical
• 13.7. Sebela Pharmaceuticals
• 13.8. ANI Pharmaceuticals, Inc.
• 13.9. Perrigo Company plc
• 13.10. Xiromed

LIST NOT EXHAUSTIVE

14. Appendix

• 14.1. About Us and Services
• 14.2. Contact Us